

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Taflopust Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

### SECTION 1. IDENTIFICATION

Product name : Taflopust Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

#### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

#### Other hazards

None known.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Glycerine	1,2,3-Propanetriol	56-81-5	$\geq 1 - < 5$ *
Taflopust	No data available	209860-87-7	$\geq 0 - < 0.1$ *

\* Actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

|| General advice : No information available.  
If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.  
In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.  
In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
3.0	12/13/2025	558015-00020	Date of first issue: 03/15/2016

---

If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	No information available.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate

---

## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.

Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	TWA (Mist)	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Mist)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Respirable mist)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (Mist)	10 mg/m <sup>3</sup>	CA QC OEL
Tafluprost	209860-87-7	TWA	0.002 µg/m <sup>3</sup> (OEB 5)	Internal
Further information: Skin, Eye				
		Wipe limit	0.02 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard

## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

### Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Organic vapor Type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Color	:	clear
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
3.0	12/13/2025	558015-00020	Date of first issue: 03/15/2016

---

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Glycerine:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

##### Tafluprost:

Acute oral toxicity : LD50 (Rat): 665 mg/kg  
LD50 (Rat): > 100 mg/kg  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg  
Application Route: Intravenous  
Target Organs: Cardio-vascular system

#### Skin corrosion/irritation

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

### Components:

#### Glycerine:

Species : Rabbit  
Result : No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Glycerine:

Species : Rabbit  
Result : No eye irritation

#### Tafluprost:

Species : Monkey  
Result : No eye irritation

#### Respiratory or skin sensitization

##### Skin sensitization

Not classified based on available information.

##### Respiratory sensitization

Not classified based on available information.

### Components:

#### Tafluprost:

Test Type : Maximization Test  
Routes of exposure : Dermal  
Species : Guinea pig  
Result : Not a skin sensitizer.

#### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Glycerine:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

||

### Tafluprost:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Chromosome aberration test in vitro  
Result: negative  
  
Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Glycerine:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

#### Tafluprost:

Species : Rat  
Application Route : Subcutaneous  
Exposure time : 24 Months  
Result : negative

Species : Mouse  
Application Route : Subcutaneous  
Exposure time : 18 Months  
Result : negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Glycerine:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative  
  
Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

## Taf luprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

### Taf luprost:

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intravenous injection  
Fertility: NOAEL: 100 µg/kg  
Result: No effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 10 µg/kg  
Result: Malformations were observed., Reduced fetal weight.
- Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 3 µg/kg
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 0.03 µg/kg  
Result: Malformations were observed.
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0.01 µg/kg
- Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 1 µg/kg
- Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0.3 µg/kg
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### STOT-single exposure

Not classified based on available information.

### Components:

#### Taf luprost:

- Target Organs : Lungs, Cardio-vascular system  
Assessment : Causes damage to organs.

### STOT-repeated exposure

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

### Components:

#### **Tafluprost:**

Target Organs : Lungs, Cardio-vascular system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

#### Components:

##### **Glycerine:**

Species : Rat  
NOAEL : 0.167 mg/l  
LOAEL : 0.622 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 13 Weeks

Species : Rat  
NOAEL : 8,000 - 10,000 mg/kg  
Application Route : Ingestion  
Exposure time : 2 y

Species : Rabbit  
NOAEL : 5,040 mg/kg  
Application Route : Skin contact  
Exposure time : 45 Weeks

#### **Tafluprost:**

Species : Rat  
LOAEL : 0.01 mg/kg  
Application Route : Intravenous  
Exposure time : 6 Months  
Target Organs : Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen

Species : Dog  
NOAEL : 0.0001 mg/kg  
LOAEL : 0.001 mg/kg  
Application Route : Intravenous  
Exposure time : 39 Weeks  
Target Organs : Cardio-vascular system, Eye  
Symptoms : Dilatation of the pupil

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

#### Components:

#### **Tafluprost:**

Eye contact : Symptoms: dryness of the eyes, Blurred vision

## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### **Glycerine:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l  
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

#### Persistence and degradability

##### Components:

##### **Glycerine:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 92 %  
Exposure time: 30 d  
Method: OECD Test Guideline 301D

#### Bioaccumulative potential

##### Components:

##### **Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1.75

##### **Tafluprost:**

Partition coefficient: n-octanol/water : log Pow: 4.5

#### Mobility in soil

No data available

#### Other adverse effects

No data available

---

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## Tafluprost Formulation

Version 3.0      Revision Date: 12/13/2025      SDS Number: 558015-00020      Date of last issue: 12/08/2025  
Date of first issue: 03/15/2016

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

Not regulated as a dangerous good

##### IATA-DGR

Not regulated as a dangerous good

##### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### TDG

Not regulated as a dangerous good

#### Special precautions for user

Not applicable

---

### SECTION 15. REGULATORY INFORMATION

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

#### Canadian lists

|| No substances are subject to CEPA Section 84 Ministerial Conditions.

---

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants

CA AB OEL / TWA : 8-hour Occupational exposure limit

CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWA EV : Time-weighted average exposure value

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Taf luprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
3.0	12/13/2025	558015-00020	Date of first issue: 03/15/2016

---

Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 12/13/2025  
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8